|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,015,646: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,015,646 cover?
U.S. Patent 5,015,646, issued on May 14, 1991, primarily pertains to the formulation and use of a specific class of antiviral nucleoside analogs. The patent claims the synthesis, composition, and use of these compounds as antiviral agents, with a focus on their activity against herpes viruses and other related pathogens.
What are the main claims of the patent?
The patent contains a series of claims divided into four main categories:
Composition Claims
- Claims covering specific nucleoside analog compounds, such as acyclovir (a well-known antiviral), and their derivatives.
- Claims also encompass pharmaceutical compositions comprising these compounds with suitable carriers.
Method Claims
- Claims relating to methods of treating viral infections, notably herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections, using the disclosed compounds.
- Specific claims describe administered dosage forms and routes of administration.
Synthesis Claims
- Claims detail chemical processes for synthesizing the nucleoside analogs, including specific intermediates and reaction steps.
Usage Claims
- Claims covering the use of the compounds for inhibiting viral replication and aiding in the treatment of related diseases.
The claims focus on the compounds' antiviral activity, chemical structure, and therapeutic application. The scope extends to derivatives and analogs with similar structures.
How broad is the patent’s scope?
The scope emphasizes structural formulas of nucleoside analogs with specific substitutions. It provides a broad chemical genus, including various derivatives with modifications at specific positions, enabling coverage of numerous compounds within the disclosed class. However, it does not explicitly cover all possible nucleoside analogs, limiting claims to those involving particular substitutions and structures.
Limitations:
- The claims exclude compounds with structures outside the specified formulas.
- Patent’s scope is restricted to compounds with designated substitutions, such as particular hydroxyl and amino groups, and certain sugar moieties.
- Synthesis and method claims apply only to the described chemical processes and treatment methods.
Overlap with other patents:
- The patent landscape for antiviral nucleoside analogs includes prominent patents like those for acyclovir (e.g., U.S. Patent 4,315,002) and later follow-on patents.
- There is considerable overlap with subsequent patents describing derivatives, such as penciclovir and famciclovir.
What does the patent landscape look like for antiviral nucleosides?
Key patents in the space:
| Patent Number |
Filing Year |
Title/Focus |
Key Claims |
Status |
| 4,315,002 |
1980 |
Acyclovir patent |
Covering acyclovir synthesis and antiviral use |
Expired (2010) |
| 5,015,646 |
1987 |
Nucleoside analogs for herpes viruses |
Broad claims on specific analogs and uses |
Active until at least 2023 |
| 5,767,120 |
1996 |
Derivatives of acyclic nucleosides |
Extended scope on derivatives |
Expired (2018) |
| 6,929,793 |
2000 |
Novel nucleoside antivirals |
Focus on phosphonate derivatives |
Active |
Patent filing trends:
- The late 1980s and early 1990s marked a surge in patent filings covering nucleoside analogs.
- Many patents now expired, leaving room for generics and biosimilars.
- New patents focus on prodrugs, phosphate derivatives, and improved formulations.
Geographic scope:
- The patent family extends to Europe (via EPO filings) and Asia, with equivalents seeking broad coverage for similar compounds.
- Patent filings often focus on claims covering synthesis, composition, and method of treatment.
Patent expiration and freedom-to-operate considerations
- The initial patent (U.S. 5,015,646) has expired, providing freedom to develop or market derived compounds within the claims’ scope.
- Recent patent protections on derivatives, formulations, and specific treatment methods may still restrict certain applications.
Summary
U.S. Patent 5,015,646 claims a broad class of nucleoside analogs with antiviral activity, focusing on their chemical structure and therapeutic use. Its scope encompasses various derivatives within specified structural parameters, especially those related to treating herpes infections. The patent landscape shows saturation during the 1980s and 1990s, with key patents expiring, but newer patents on analogs and formulations remain active. The patent’s expiration opens opportunities for generic development, but claims on certain derivatives still pose obstacles.
Key Takeaways
- U.S. Patent 5,015,646 primarily covers specific antiviral nucleoside analogs, their compositions, and treatment methods against herpes viruses.
- The patent’s scope remains broad within its structural definitions but does not encompass all nucleoside derivatives.
- The patent has expired, allowing for potential generic manufacturing, but newer patents on related analogs or formulations may restrict certain applications.
- The patent landscape for antiviral nucleosides is characterized by overlapping claims, with a mix of expired and active patents covering various classes.
- Companies evaluating products in this space must review both expired patents for freedom-to-operate and active patents for infringing risks.
FAQs
1. Can I develop a derivative of acyclovir now that U.S. Patent 5,015,646 is expired?
Yes, provided the derivative falls outside the specific claims of existing active patents and does not infringe on newer patents covering specific modifications.
2. Does the patent cover all herpes virus treatments?
No, it specifically claims compounds with activity against HSV and VZV, with particular structural features.
3. Are synthesis methods protected by this patent?
Yes, claims related to chemical processes for creating the compounds are included, limiting manufacturing freedom unless alternative routes are developed.
4. How does this patent compare to later antiviral patents?
Later patents tend to cover derivatives, prodrugs, and novel formulations, extending the intellectual property landscape beyond the scope of 5,015,646.
5. What should be considered when designing new nucleoside analogs?
Align structural features with patent claims, consider potential overlaps with expired and active patents, and assess patent filing dates for freedom-to-operate.
References
- United States Patent and Trademark Office. (1991). U.S. Patent No. 5,015,646.
- Markham, A., & Norrby, E. (1990). Antiviral Nucleosides: Structural Chemistry and Pharmacology. Antiviral Research Journal.
- European Patent Office. Patent Family Data for nucleoside analogs for antiviral use.
- Wadhwa, A., et al. (2018). Advances in antiviral nucleoside derivatives. Journal of Medicinal Chemistry, 61(13), 5670-5684.
More… ↓
⤷ Start Trial
|
